Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
24 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
For best results when printing this announcement, please click on link below: Yext Board Approves Long-Term Performance Equity Award For CEO Yext, Inc. ( ) (NYSE: YEXT), the enterprise marketing platform for an agentic world (“Yext” or “Company”), announced that the Board of Directors (the “Board”) has approved a new,
Outlook Therapeutics appointed Greg DiPasquale chief commercial officer. He will lead commercialization efforts for LYTENAVA as the company prepares a U.S. launch before the end of 2026.
Matternet said management will participate in several upcoming investor conferences in October, including the Maxim Growth Summit, ThinkEquity Small Cap Conference and LD Micro Main Event.
Dow Jones’ 5 p.m. ET roundup highlights a series of company updates, including Microsoft’s new Xbox unit, PepsiCo’s outlook cut, Viatris’ planned Pacira BioSciences acquisition and Samsung’s profit outlook.
Dow Jones Newswires listed a series of corporate and regulatory headlines, including Microsoft, PepsiCo, Devon Energy, Viatris and Samsung. The package also included legal, production and deal updates across several companies.
PepsiCo cut its full-year earnings outlook as inflation, higher advertising costs and continued weakness in North America weighed on results. The company said it is working to reduce expenses and revive sales.
NVIDIA said it will commit $1 billion over five years to support U.S. science, including quantum computing, healthcare and energy security. The company said the effort is part of its collaboration with the Genesis Mission and U.S. research institutions.
Pacira BioSciences filed an 8-K saying it and Parent issued a joint press release announcing execution of the merger agreement. The filing says the press release is furnished as Exhibit 99.1 to the report.
Viatris said it and Pacira issued a joint press release announcing entry into a merger agreement. The company also made an investor presentation available on Oct. 8, 2026.
BioNexus Gene Lab said it entered a definitive CogniAI Healthcare Licence and Strategic Collaboration Agreement with Ruanyun Edai Technology. The company said the deal remains subject to closing conditions and pending share issuances.
The EPCORE DLBCL-2 trial showed that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% compared to R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients.
Oscar Health (NYSE: OSCR ) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. The full earnings call is available at Summary Oscar Health report
Amylyx Pharma (NASDAQ: AMLX ) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. The full earnings call is available at Summary Amylyx Pharma re
On Thursday, Illumina (NASDAQ: ILMN ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary Illumina reported strong Q2 2026 performance with revenue gr
On Wednesday, GRAIL (NASDAQ: GRAL ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit The full earnings call is available at Summary GRAIL reported a strong second quarter 2026
Societe Generale SA submitted a Rule 8.3 Form 8.3 public opening position disclosure for Spire Healthcare Group plc.
The company said second-quarter revenue rose 30.1% year over year to 1.39 billion RMB, while net income increased 35.6% to 413.2 million RMB. Yuanbao also said cash reserves totaled 5.16 billion RMB and it had repurchased about 114,000 ADS for US$1.6 million as of Aug. 31, 2026.
Societe Generale SA published an RNS on 10 September 2026 containing a Rule 8.3 public opening position disclosure/dealing disclosure. The filing concerns positions in relevant securities representing at least 1%.
Spire Healthcare Group plc disclosed a Form 8.3 under Rule 8.3 of the Takeover Code, covering an opening position disclosure/dealing disclosure by a person with interests.
Societe Generale SA submitted an RNS on 04 September 2026 for Spire Healthcare Group plc, disclosing public opening position and dealing information under Rule 8.3 (Form 8.3).
Societe Generale SA filed an RNS for a Form 8.3 public opening position dealing disclosure for Spire Healthcare Group plc, under Rule 8.3 of the Takeover Code.
Millions of Medicare beneficiaries will gain access to obesity drugs for the first time starting Wednesday under CMS’ temporary Bridge program, a federal initiative designed to expand GLP-1 obesity drug coverage for eligible seniors at a $50 monthly copay. The program marks a major shift in Medicare coverage. While Med
GE HealthCare Technologies submits filing to SEC, disclosure details unknown
GE HealthCare Technologies Inc. submits filing to SEC. The filing is 4 KB in size and was filed on May 26, 2026.